With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx
Executive Summary
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.